论文信息 - The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC). - 字舞流文

The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC).

J. Tabernero | J. Bridgewater | B. Markman | C. Pericay | K. Bencardino | S. Siena | J. Pérez-Fidalgo | R. García-Carbonero | L. Manenti | L. Samuel | G. Aprile | C. Mancao | M. Kozloff | J. Mckendrick | A. Cubillo | S. Lutrino | A. Waterston | A. Strickland | I. Moya | A. Cervantes-Ruipérez